Rectification of the Register – A Singapore Perspective

Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co [2017] SGHC 322 I.             Introduction In the recent case of Novartis (Singapore) Pte Ltd v Bristol-Myers Squibb Pharma Co [2017] SGHC 322, the Singapore High Court addressed, for the first time, key procedural issues associated with corrections to patent forms and priority data, as well as […]

Post-Grant Amendments from Method of Treatment to Swiss-Style – The Singapore Position Clarified

Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2017] SGCA 45   Introduction   In the landmark case of Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2017] SGCA 45, the Singapore Court of Appeal explored, inter alia, the permissibility of amending method of treatment claims to Swiss-style claims.   Significantly, the matter was heard […]

Singapore IP Policy Cases: IPOS Strengthens the Criteria on Assessment of Post-grant Amendments

In Singapore, post-grant amendments are allowed at the discretion of the court or the Registrar.  The amendments are assessed under Section 84(3) of the Patents Act. The court or the Registrar may allow the amendments to the specification of the patent if: (a)    The amendment does not result in disclosing additional matter; or (b)    The […]

Singapore Mirandah and Trademark cases: CAESARSTONE Prevails over CAESAR

On March 29, 2016, the High Court of Singapore overturned the Intellectual Property Office of Singapore’s (IPOS’s) decision to refuse registration of Caesarstone Sdot-Yam Ltd’s mark CAESARSTONE for goods in Class 19.   Appellant’s Mark Respondent’s Mark       The respondent, Ceramiche Caesar SpA, had a prior registration in Class 19 for goods including […]